Personalis Inc. has announced an expansion of its partnership with Tempus AI, Inc., following the entry into Amendment No. 4 to their existing Commercialization and Reference Laboratory Agreement. Effective July 8, 2025, this amendment authorizes Tempus to market Personalis' ultra-sensitive NeXT Personal® test for minimal residual disease in colorectal cancer, in addition to its current use in breast cancer, lung cancer, and immuno-oncology monitoring. The agreement, which has been extended to November 2029, also includes exclusivity provisions for colorectal cancer, prohibiting third parties from marketing similar tests and restricting Tempus from promoting competing assays until the end of 2028. This strategic move aims to strengthen their collaboration and market presence in the oncology diagnostics field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.